National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Value-of-information (VOI)

value-of-information techniques assess the expected costs of uncertainty surrounding a decision made on the basis of current information, in order to determine whether further research should be conducted and how this should be designed.

Venetoclax (Venclyxto®) in combination with obinutuzumab (Gazyvaro®). HTA ID: 20046

Venetoclax in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.


NCPE Assessment Process Complete
Rapid review commissioned 07/10/2020
Rapid review completed 22/10/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of venetoclax in combination with obinutuzumab compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 27/10/2020
Pre-submission consultation with Applicant 30/11/2020
Current Status Awaiting HTA submission from Applicant